Advice
in the absence of a submission from the holder of the marketing authorisation:
trametinib (Mekinist®) is not recommended for use within NHS Scotland.
Indication under review: in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice68KB (PDF)
Medicine details
- Medicine name:
- trametinib 0.5mg, 2mg film-coated tablets (Mekinist)
- SMC ID:
- 1264/17
- Indication:
- In combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 July 2017